What is the projected market valuation of the Lung In-vitro Model Market by 2035?

The Lung In-vitro Model Market is projected to reach a valuation of 4.811 USD Billion by 2035. Read More

What was the market valuation of the Lung In-vitro Model Market in 2024?

In 2024, the Lung In-vitro Model Market was valued at 0.7994 USD Billion. Read More

What is the expected CAGR for the Lung In-vitro Model Market during the forecast period 2025 - 2035?

The expected CAGR for the Lung In-vitro Model Market during the forecast period 2025 - 2035 is 17.72%. Read More

Which companies are considered key players in the Lung In-vitro Model Market?

Key players in the Lung In-vitro Model Market include Emulate Inc, Mimetas, TissUse GmbH, InSphero AG, Organovo Holdings Inc, Synlogic Inc, Acelity L.P. Inc, and Reinnervate Ltd. Read More

What are the main types of Lung In-vitro Models and their market valuations?

The main types include 2D Lung In-vitro Models valued at 1.9235 USD Billion, 3D Lung In-vitro Models at 1.4426 USD Billion, and Co-Culture Lung In-vitro Models at 1.4449 USD Billion. Read More

What applications are driving the Lung In-vitro Model Market?

Key applications driving the market include Drug Discovery and Development valued at 1.9255 USD Billion and Toxicological Studies at 1.4446 USD Billion. Read More

Which diseases are primarily modeled using Lung In-vitro Models?

Diseases modeled include Chronic Obstructive Pulmonary Disease valued at 1.4391 USD Billion and Lung Cancer at 1.4397 USD Billion. Read More

What formats are available for Lung In-vitro Models and their respective market sizes?

Available formats include Fixed models valued at 1.9255 USD Billion, Frozen models at 1.4433 USD Billion, and Live models at 1.4422 USD Billion. Read More

Who are the primary end-users of Lung In-vitro Models?

Primary end-users include Pharmaceutical and Biotechnology Companies valued at 2.4055 USD Billion and Academic and Research Institutions at 1.4433 USD Billion. Read More

How does the market for Lung In-vitro Models compare across different segments?

The market shows varied valuations across segments, with Drug Discovery and Development leading at 1.9255 USD Billion, followed by Toxicological Studies at 1.4446 USD Billion. Read More

Lung In Vitro Model Market

ID: MRFR/HC/25543-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Lung In-vitro Model Market Research Report By Type (2D Lung In-vitro Model, 3D Lung In-vitro Model, Co-Culture Lung In-vitro Model), By Application (Drug Discovery and Development, Toxicological Studies, Personalized Medicine, Disease Modeling), By Disease Model (Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer), By Format (Frozen, Fixed, Live), By End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 2D Lung In-vitro Model
4.1.2 3D Lung In-vitro Model
4.1.3 Co-Culture Lung In-vitro Model
4.2 Healthcare, BY Application (USD Billion)
4.2.1 Drug Discovery and Development
4.2.2 Toxicological Studies
4.2.3 Personalized Medicine
4.2.4 Disease Modeling
4.3 Healthcare, BY Disease Model (USD Billion)
4.3.1 Idiopathic Pulmonary Fibrosis
4.3.2 Chronic Obstructive Pulmonary Disease
4.3.3 Asthma
4.3.4 Lung Cancer
4.4 Healthcare, BY Format (USD Billion)
4.4.1 Frozen
4.4.2 Fixed
4.4.3 Live
4.5 Healthcare, BY End-user (USD Billion)
4.5.1 Pharmaceutical and Biotechnology Companies
4.5.2 Academic and Research Institutions
4.5.3 Contract Research Organizations
4.6 Healthcare, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Emulate Inc (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Mimetas (NL)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 TissUse GmbH (DE)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 InSphero AG (CH)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Organovo Holdings Inc (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Synlogic Inc (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Acelity L.P. Inc (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Reinnervate Ltd (GB)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY APPLICATION
6.5 US MARKET ANALYSIS BY DISEASE MODEL
6.6 US MARKET ANALYSIS BY FORMAT
6.7 US MARKET ANALYSIS BY END-USER
6.8 CANADA MARKET ANALYSIS BY TYPE
6.9 CANADA MARKET ANALYSIS BY APPLICATION
6.10 CANADA MARKET ANALYSIS BY DISEASE MODEL
6.11 CANADA MARKET ANALYSIS BY FORMAT
6.12 CANADA MARKET ANALYSIS BY END-USER
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY TYPE
6.15 GERMANY MARKET ANALYSIS BY APPLICATION
6.16 GERMANY MARKET ANALYSIS BY DISEASE MODEL
6.17 GERMANY MARKET ANALYSIS BY FORMAT
6.18 GERMANY MARKET ANALYSIS BY END-USER
6.19 UK MARKET ANALYSIS BY TYPE
6.20 UK MARKET ANALYSIS BY APPLICATION
6.21 UK MARKET ANALYSIS BY DISEASE MODEL
6.22 UK MARKET ANALYSIS BY FORMAT
6.23 UK MARKET ANALYSIS BY END-USER
6.24 FRANCE MARKET ANALYSIS BY TYPE
6.25 FRANCE MARKET ANALYSIS BY APPLICATION
6.26 FRANCE MARKET ANALYSIS BY DISEASE MODEL
6.27 FRANCE MARKET ANALYSIS BY FORMAT
6.28 FRANCE MARKET ANALYSIS BY END-USER
6.29 RUSSIA MARKET ANALYSIS BY TYPE
6.30 RUSSIA MARKET ANALYSIS BY APPLICATION
6.31 RUSSIA MARKET ANALYSIS BY DISEASE MODEL
6.32 RUSSIA MARKET ANALYSIS BY FORMAT
6.33 RUSSIA MARKET ANALYSIS BY END-USER
6.34 ITALY MARKET ANALYSIS BY TYPE
6.35 ITALY MARKET ANALYSIS BY APPLICATION
6.36 ITALY MARKET ANALYSIS BY DISEASE MODEL
6.37 ITALY MARKET ANALYSIS BY FORMAT
6.38 ITALY MARKET ANALYSIS BY END-USER
6.39 SPAIN MARKET ANALYSIS BY TYPE
6.40 SPAIN MARKET ANALYSIS BY APPLICATION
6.41 SPAIN MARKET ANALYSIS BY DISEASE MODEL
6.42 SPAIN MARKET ANALYSIS BY FORMAT
6.43 SPAIN MARKET ANALYSIS BY END-USER
6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.45 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
6.46 REST OF EUROPE MARKET ANALYSIS BY DISEASE MODEL
6.47 REST OF EUROPE MARKET ANALYSIS BY FORMAT
6.48 REST OF EUROPE MARKET ANALYSIS BY END-USER
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY TYPE
6.51 CHINA MARKET ANALYSIS BY APPLICATION
6.52 CHINA MARKET ANALYSIS BY DISEASE MODEL
6.53 CHINA MARKET ANALYSIS BY FORMAT
6.54 CHINA MARKET ANALYSIS BY END-USER
6.55 INDIA MARKET ANALYSIS BY TYPE
6.56 INDIA MARKET ANALYSIS BY APPLICATION
6.57 INDIA MARKET ANALYSIS BY DISEASE MODEL
6.58 INDIA MARKET ANALYSIS BY FORMAT
6.59 INDIA MARKET ANALYSIS BY END-USER
6.60 JAPAN MARKET ANALYSIS BY TYPE
6.61 JAPAN MARKET ANALYSIS BY APPLICATION
6.62 JAPAN MARKET ANALYSIS BY DISEASE MODEL
6.63 JAPAN MARKET ANALYSIS BY FORMAT
6.64 JAPAN MARKET ANALYSIS BY END-USER
6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.66 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
6.67 SOUTH KOREA MARKET ANALYSIS BY DISEASE MODEL
6.68 SOUTH KOREA MARKET ANALYSIS BY FORMAT
6.69 SOUTH KOREA MARKET ANALYSIS BY END-USER
6.70 MALAYSIA MARKET ANALYSIS BY TYPE
6.71 MALAYSIA MARKET ANALYSIS BY APPLICATION
6.72 MALAYSIA MARKET ANALYSIS BY DISEASE MODEL
6.73 MALAYSIA MARKET ANALYSIS BY FORMAT
6.74 MALAYSIA MARKET ANALYSIS BY END-USER
6.75 THAILAND MARKET ANALYSIS BY TYPE
6.76 THAILAND MARKET ANALYSIS BY APPLICATION
6.77 THAILAND MARKET ANALYSIS BY DISEASE MODEL
6.78 THAILAND MARKET ANALYSIS BY FORMAT
6.79 THAILAND MARKET ANALYSIS BY END-USER
6.80 INDONESIA MARKET ANALYSIS BY TYPE
6.81 INDONESIA MARKET ANALYSIS BY APPLICATION
6.82 INDONESIA MARKET ANALYSIS BY DISEASE MODEL
6.83 INDONESIA MARKET ANALYSIS BY FORMAT
6.84 INDONESIA MARKET ANALYSIS BY END-USER
6.85 REST OF APAC MARKET ANALYSIS BY TYPE
6.86 REST OF APAC MARKET ANALYSIS BY APPLICATION
6.87 REST OF APAC MARKET ANALYSIS BY DISEASE MODEL
6.88 REST OF APAC MARKET ANALYSIS BY FORMAT
6.89 REST OF APAC MARKET ANALYSIS BY END-USER
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY TYPE
6.92 BRAZIL MARKET ANALYSIS BY APPLICATION
6.93 BRAZIL MARKET ANALYSIS BY DISEASE MODEL
6.94 BRAZIL MARKET ANALYSIS BY FORMAT
6.95 BRAZIL MARKET ANALYSIS BY END-USER
6.96 MEXICO MARKET ANALYSIS BY TYPE
6.97 MEXICO MARKET ANALYSIS BY APPLICATION
6.98 MEXICO MARKET ANALYSIS BY DISEASE MODEL
6.99 MEXICO MARKET ANALYSIS BY FORMAT
6.100 MEXICO MARKET ANALYSIS BY END-USER
6.101 ARGENTINA MARKET ANALYSIS BY TYPE
6.102 ARGENTINA MARKET ANALYSIS BY APPLICATION
6.103 ARGENTINA MARKET ANALYSIS BY DISEASE MODEL
6.104 ARGENTINA MARKET ANALYSIS BY FORMAT
6.105 ARGENTINA MARKET ANALYSIS BY END-USER
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE MODEL
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMAT
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.113 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
6.114 GCC COUNTRIES MARKET ANALYSIS BY DISEASE MODEL
6.115 GCC COUNTRIES MARKET ANALYSIS BY FORMAT
6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USER
6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.118 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
6.119 SOUTH AFRICA MARKET ANALYSIS BY DISEASE MODEL
6.120 SOUTH AFRICA MARKET ANALYSIS BY FORMAT
6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USER
6.122 REST OF MEA MARKET ANALYSIS BY TYPE
6.123 REST OF MEA MARKET ANALYSIS BY APPLICATION
6.124 REST OF MEA MARKET ANALYSIS BY DISEASE MODEL
6.125 REST OF MEA MARKET ANALYSIS BY FORMAT
6.126 REST OF MEA MARKET ANALYSIS BY END-USER
6.127 KEY BUYING CRITERIA OF HEALTHCARE
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF HEALTHCARE
6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.135 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
6.136 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
6.137 HEALTHCARE, BY DISEASE MODEL, 2024 (% SHARE)
6.138 HEALTHCARE, BY DISEASE MODEL, 2024 TO 2035 (USD Billion)
6.139 HEALTHCARE, BY FORMAT, 2024 (% SHARE)
6.140 HEALTHCARE, BY FORMAT, 2024 TO 2035 (USD Billion)
6.141 HEALTHCARE, BY END-USER, 2024 (% SHARE)
6.142 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
7.2.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.2.4 BY FORMAT, 2025-2035 (USD Billion)
7.2.5 BY END-USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
7.3.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.3.4 BY FORMAT, 2025-2035 (USD Billion)
7.3.5 BY END-USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
7.4.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.4.4 BY FORMAT, 2025-2035 (USD Billion)
7.4.5 BY END-USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
7.5.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.5.4 BY FORMAT, 2025-2035 (USD Billion)
7.5.5 BY END-USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
7.6.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.6.4 BY FORMAT, 2025-2035 (USD Billion)
7.6.5 BY END-USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
7.7.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.7.4 BY FORMAT, 2025-2035 (USD Billion)
7.7.5 BY END-USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
7.8.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.8.4 BY FORMAT, 2025-2035 (USD Billion)
7.8.5 BY END-USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
7.9.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.9.4 BY FORMAT, 2025-2035 (USD Billion)
7.9.5 BY END-USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
7.10.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.10.4 BY FORMAT, 2025-2035 (USD Billion)
7.10.5 BY END-USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
7.11.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.11.4 BY FORMAT, 2025-2035 (USD Billion)
7.11.5 BY END-USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
7.12.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.12.4 BY FORMAT, 2025-2035 (USD Billion)
7.12.5 BY END-USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
7.13.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.13.4 BY FORMAT, 2025-2035 (USD Billion)
7.13.5 BY END-USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
7.14.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.14.4 BY FORMAT, 2025-2035 (USD Billion)
7.14.5 BY END-USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
7.15.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.15.4 BY FORMAT, 2025-2035 (USD Billion)
7.15.5 BY END-USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
7.16.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.16.4 BY FORMAT, 2025-2035 (USD Billion)
7.16.5 BY END-USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
7.17.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.17.4 BY FORMAT, 2025-2035 (USD Billion)
7.17.5 BY END-USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
7.18.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.18.4 BY FORMAT, 2025-2035 (USD Billion)
7.18.5 BY END-USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
7.19.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.19.4 BY FORMAT, 2025-2035 (USD Billion)
7.19.5 BY END-USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
7.20.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.20.4 BY FORMAT, 2025-2035 (USD Billion)
7.20.5 BY END-USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
7.21.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.21.4 BY FORMAT, 2025-2035 (USD Billion)
7.21.5 BY END-USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
7.22.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.22.4 BY FORMAT, 2025-2035 (USD Billion)
7.22.5 BY END-USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
7.23.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.23.4 BY FORMAT, 2025-2035 (USD Billion)
7.23.5 BY END-USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
7.24.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.24.4 BY FORMAT, 2025-2035 (USD Billion)
7.24.5 BY END-USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
7.25.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.25.4 BY FORMAT, 2025-2035 (USD Billion)
7.25.5 BY END-USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
7.26.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.26.4 BY FORMAT, 2025-2035 (USD Billion)
7.26.5 BY END-USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
7.27.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.27.4 BY FORMAT, 2025-2035 (USD Billion)
7.27.5 BY END-USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
7.28.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.28.4 BY FORMAT, 2025-2035 (USD Billion)
7.28.5 BY END-USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
7.29.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.29.4 BY FORMAT, 2025-2035 (USD Billion)
7.29.5 BY END-USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
7.30.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
7.30.4 BY FORMAT, 2025-2035 (USD Billion)
7.30.5 BY END-USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

2D Lung In-vitro Model
3D Lung In-vitro Model
Co-Culture Lung In-vitro Model

Healthcare By Application (USD Billion, 2025-2035)

Drug Discovery and Development
Toxicological Studies
Personalized Medicine
Disease Modeling

Healthcare By Disease Model (USD Billion, 2025-2035)

Idiopathic Pulmonary Fibrosis
Chronic Obstructive Pulmonary Disease
Asthma
Lung Cancer

Healthcare By Format (USD Billion, 2025-2035)

Frozen
Fixed
Live

Healthcare By End-user (USD Billion, 2025-2035)

Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
Contract Research Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓